Immediate and long-term results of percutaneous balloon aortic valvuloplasty: a report of 33 procedures

The purpose of this study was to evaluate the immediate and long-term clinical and haemodynamic effects of Percutaneous Balloon Aortic Valvuloplasty (PBAV). Thirty-three procedures were performed in 27 patients, 11 males and 16 females with a mean age of 72 years. The peak to peak systolic gradient across the aortic valve decreased by 52%, from 67 ± 24 mmHg to 31 ± 15 mmHg (p< 0.0001) and the aortic valve area increased by 35%, from 0.48 ±0.16 to 0.67 ± 0.21 cm² (p <0.001) after PBAV. There were no procedural deaths. Minor complications occurred in seven patients. Eighty-one per cent of patients (27 procedures) showed immediate symptomatic improvement, five remained symptomatic and one died in hospital before discharge. In a mean follow-up of 17 ± 12 months (range six to 38 months), eight patients died due to congestive cardiac failure, six underwent repeat PBAV, three died due to noncardiac causes and three had recurrent symptoms controlled on medical therapy. Event free survival at 15 months was 43%. In conclusion PBAV produces a satisfactory immediate clinical and haemodynamic result, however, considering the high rate of symptom recurrence, this procedure has a beneficial role only in short-term palliation of severely symptomatic patients who are unable to undergo aortic valve replacement. (Aust NZ J Med 1992; 22: 647ndash;651.)     

Repeat balloon aortic valvuloplasty

This paper attempts to determine limitations and indications of performing a second balloon aortic valvuloplasty procedure (BAV2) because of restenosis, which is the major limitation of this technique. From September 1985 to December 1989, 357 patients underwent a primary BAV (BAV1) and 67 patients had a BAV2. Forty-two patients (group A) had repeat catheterization because they were markedly symptomatic 11 ± 7 months after BAV1. Twenty-five patients (group B) came from a group of 73 patients who had been systematically scheduled for repeat catheterization in order to evaluate the hemodynamic restenosis rate 8 ± 3 months after BAV. At time of BAV2 most of the patients of group A were severely disabled. Comparison of pre-BAV2 gradient and aortic valve area with pre-BAV1 measurements showed in a slightly less severe degree of aortic stenosis in group A and in group B with any difference in cardiac index and ejection fraction. Immediately following BAV2, the gradient decreased from 72 ± 22 to 33 ± 15 mm Hg (P ± and aortic valve area increased from 0.56 ± 0.18 to 0.85 ± 0.28 cm ²) (p < 0.001) in group A. In group B, gradient decreased from 68 ± 15 to 33 ± 15 mm Hg (p < 0.001) and aortic valve area increased from 0.70 ± 0.16 to 0.90 ± 0.25 cm² (p < 0.001). Comparison of the post-BAV2 peak systolic gradient, aortic valve area, ejection fraction, and cardiac index with post-BAV1 measurements revealed no significant differences in the two groups, but the absolute increase in aortic valve area obtained at BAV2 was significantly less than at BAV1 in group B (0.20 ± 0.22 vs 0.31 ± 0.16 cm² p < 0.02). The larger balloon size used for BAV2 than for BAV1 did not increase the final valve area at BAV2. In-hospital mortality was 3%. The use of a better profiled catheter with an arterial introducer explained the lower rate of vascular complications (4%). This report demonstrates that when BAV is indicated a second procedure can be performed safely and with low risk in symptomatic patients. © 1992 Wiley-Liss, Inc.     

经皮二尖瓣球囊成形术治疗二尖瓣狭窄伴主动脉瓣关闭不全的疗效评价

目的　探讨风湿性心脏病 (RHD)二尖瓣狭窄 (MS)合并轻、中度主动脉瓣关闭不全 (AR)患者行经皮二尖瓣球囊成形术 (PBMV)的效果。方法　将 2 6例MS合并轻、中度AR患者 (A组 )和 34例单纯MS患者 (B组 )的PBMV术后即刻及随访结果作对比研究。结果　A组左心房平均压力(MLAP)从术前 2 3 5± 4 6mmHg降至 11 2± 2 9mmHg(P <0 0 1) ,二尖瓣跨瓣压差 (MVG)从 17 2±7 7mmHg降至 2 3± 2 6mmHg(P <0 0 1) ,二尖瓣口面积 (MVA)从 1 1± 0 2cm2 增至 2 1± 0 2cm2(P <0 0 1) ,左心房内径 (LAD)从 43 3± 5 0mm降至 36 4± 3 7mm(P <0 0 1)。二尖瓣区舒张期杂音消失率为 73%。心功能分级 (NYHA)从术前 2 7± 0 5级改善至 1 1± 0 7级 (P <0 0 1)。随访与术后比较 ,除MVA外各项指标均无显著性差异 (P >0 0 5 )。以上各项参数与B组比较 ,差异均无显著性(P >0 0 5 )。且A组随访左心室内径 (LVD)仍在正常范围 ,亦无主动脉瓣返流增加。结论　对于MS合并轻、中度AR ,PBMV是一种有效和安全的治疗措施 ,应列入PBMV的手术适应症。     

Assessment of the “long sheath” technique for percutaneous aortic balloon valvuloplasty

A 100 cm-long 16.5 F valvuloplasty catheter introducer was assessed as an adjunct for percutaneous transluminal aortic valvuloplasty (PTAV) via the femoral artery in 31 patients with severe aortic stenosis. Observed improvements in peak systolic gradient (81.6 ± 29.9 mm Hg vs. 35.5 ± 16.0 mm Hg, P < 0.000001) and aortic valve area (0.6 ± 0.4 cm² vs. 1.0 ± 0.6 cm², P < 0.00001) were similar to those achieved in a control group (C) of 17 patients in which no femoral sheath was used. However, a shorter procedure duration (211 ± 81 min vs. 117 ± 30 min, P < 0.001) and a reduced rate of vascular complications at the femoral puncture site (41% vs. 6.5%) were observed in patients in whom the long sheath (LS) technique was used. The frequency of other PTAV-related complications was comparable (C = 35%, LS = 29%, P = n.s.). Other technical advantages of this device are: 1) prevention of looping and bending of the balloon catheter in tortuous vessels and easy positioning of the balloon across the aortic orifice provided by the LS trackability, 2) stabilisation of the balloon during inflation, 3) monitoring of supravalvular aortic pressure provided by the side-arm of the LS and reliable measurement of systolic gradient, and 4) the ability to perform aortograms without the need of another catheter in the ascending aorta. Thus, in our experience, the long sheath technique is a valuable adjunct for PTAV.     

经皮球囊肺动脉瓣成型术治疗肺动脉瓣狭窄86例临床分析

目的评价经皮球囊肺动脉瓣成形术(PBPV)治疗肺动脉瓣狭窄(PS)的近期和远期疗效及安全性.方法总结近10年行PBPV术86例患者术后即刻、术后3天、术后3个月、术后1年的心电图、心脏彩超等检查结果,观察PBPV的安全可靠性,并与同期外科手术的疗效比较.结果 PBPV术后即刻右心室收缩压由(98±28)mmHg降至(56±19)mmHg(P＜0.01),肺动脉与右心室跨瓣压差(ΔP)由(64±27)mmHg降至(34±11)mmHg(P＜0.01);心电图Tv1由直立变为倒置26例(30%).术后3天、3个月及1年经超声测定ΔP分别为(21±9)mmHg、(13±7)mmHg、(10±5)mmHg;心电图Tv1变为倒置例数分别为64例、84例和85例,与同期外科手术疗效比较差异无显著性.结论 PBPV术后即刻右心室压力可明显下降,若病例选择适当,几乎可以代替外科手术.PBPV操作简便,疗效可靠,不失为治疗PS的首选方案.     

肺动脉瓣球囊扩张术前后应用多普勒超声估测跨瓣压差的临床价值研究

目的 通过与心导管测量对比来评价经皮肺动脉瓣球囊成形术（PBPV）前后应用Doppler超声心动图估测跨瓣压差的临床价值。方法 对178例患者在行PBPV术前利用Doppler测量肺动脉瓣跨瓣压差（△P’）,与相应的心导管测量值（△P）作相关性分析;并利用Doppler对PBPV术后48例患者进行了4～102个月（平均19.5个月）的随访。结果Doppler测量的△P’值与导管测量的△P值之间有着良好的直线相关性,r值为0.80,P<0.05;随访中Doppler测量的△P’值与PBPV术后即刻导管测量的△P值之间差异无显著性（P=0.05）。结论Doppler超声作为一种准确、无创、简便而有效的检查方法,对估计PBPV术前肺动脉瓣狭窄程度,评价术后疗效有较高的临床应用价值。     

Management of pediatric patients with isolated valvar aortic stenosis by balloon aortic valvuloplasty

Moderate to severe aortic stenosis in children requires an initial procedure to improve the stenosis and often additional procedures for recurrent stenosis or aortic insufficiency before adulthood. The purpose of this study was to evaluate children who underwent balloon valvuloplasty and were followed with a specific management plan. Twenty-two children with aortic stenosis underwent balloon valvuloplasty and were followed on a regular basis. Repeat valvuloplasty was performed if indicated. The initial gradient was reduced from 63 ± 9 mmHg to 28 ± 8 mmHg (P<0.001). There were no deaths and only one major complication, which had no sequelae. Average follow-up was 61 ± 23 months. Three patients required valve replacement 39–76 months after valvuloplasty for progressive insufficiency. Seven patients underwent successful repeat valvuloplasty. The overall probability of survival without surgical intervention was 75% at 100 months. Balloon valvuloplasty is an effective intermediate palliation for aortic stenosis and is an acceptable alternative to surgical valvotomy. Repeat valvuloplasty is successful without additional risk. In a subgroup of patients, aortic insufficiency is progressive and will require surgical intervention. © 1996 Wiley-Liss, Inc.     

Catheter balloon valvuloplasty of stenotic aortic valves--Part II: Balloon valvuloplasty during life subsequent tissue examination.

This review describes 23 patients with aortic valve stenosis who underwent balloon valvuloplasty during life and had subsequent valve tissue examined at the time of aortic valve replacement or at necropsy. Of 23 stenotic aortic valves, 17 were examined within 30 days (early) after balloon dilation. Of these 94% had nonrheumatic (nonfused commissures) etiologies for the aortic stenosis. Of the 6 valves examined after 30 days (late) (restenosis), mechanisms of restenosis involve refusion of split commissures and probable elastic recoil. Clinical prediction of the aortic stenosis etiology prior to balloon valvuloplasty may help predict short- and long-term success of the dilation procedure.     

Acute disseminated intravascular coagulation after percutaneous balloon aortic valvuloplasty in a cirrhotic patient

We report the case of a 71-year-old man presenting a histologicallyproven liver cirrhosis with compensated disseminated intravascularcoagulation and calcified aortic stenosis. This coagulationdisorder became clinically and biologically severe during orsoon after percutaneous balloon aortic valvuloplasty. In a cirrhotic patient with compensated disseminated intravascularcoagulation, the procedure can induce life-threatening bleedingdisorders     

Use of a 3 French system for balloon aortic valvuloplasty in infants.

For infants with valvar aortic stenosis, balloon aortic valvuloplasty has supplanted surgical valvotomy as the initial treatment of choice at most institutions. Technological innovations have resulted in further miniaturization of balloon dilation catheters, allowing this procedure to be performed through smaller sheath sizes. Currently, the Tyshak-Mini balloon dilation catheter (B. Braun Medical) allows passage of up to an 8 mm dilation balloon catheter through a 3 Fr hemostatic sheath. The efficacy of this system for the treatment of valvar aortic stenosis in infants less than 6 months of age was evaluated in 20 patients undergoing 22 procedures. Mean age at the time of intervention was 26 +/- 46 days. Mean transvalvar gradient was 76 +/- 22 mm Hg prior to balloon dilation. Following balloon valvuloplasty, residual gradient was 26 +/- 12 mm Hg, reflecting a mean change in peak-to-peak gradient of 49 +/- 19 mm Hg. Postintervention increase in aortic insufficiency was one grade or less in 19/22 procedures, two grades in 2 procedures, and three grades in 1 procedure. There were no significant vascular complications reported immediately following the procedure. Repeat valvuloplasty was performed in three patients in which the 3 Fr system was used in two patients. The 3 Fr system for balloon aortic valvuloplasty in infants less than 6 months of age is effective and safe.     

Balloon aortic valvuloplasty in elderly patients at high risk for surgery, or inoperable: Immediate and mid-term results

Although aortic valve replacement is undoubtedly the treatmentof choice for aortic valve stenosis, balloon aortic valvuloplastymay represent the only possible treatment for some frail elderlypatients who may have additional medical problems. We evaluatedimmediate and 1-year results of balloon aortic valvuloplastyin 86 patients 80 years with severe aortic stenosis. Mean agewas 84±3 years. Forty-four % were 85 years or older.Mean gradient decreased from 68 to 26 mmHg and valve area increasedfrom 0•53 to 0•96 cm² (P<0•05). There weretwo per-procedural deaths. No local vascular complication wasobserved During the follow-up (13±9 months), 27 patientsdied, four had repeat balloon aortic valvuloplasty and eightunderwent aortic valve replacement. Persistent clinical improvementwas observed in 78% of the surviving patients. One-year actuarialsurvival rate was 73%. Balloon aortic valvuloplasty appearsto be a safe and valuable technique in cases where surgery cannotbe performed or carries a very high risk.     

Outcomes of concomitant percutaneous coronary intervention and balloon aortic valvuloplasty

Background: Coronary artery disease often coexists with severe aortic stenosis. The feasibility and safety of combined balloon aortic valvuloplasty (BAV) and percutaneous coronary intervention (PCI) are unknown. Aim: To compare outcomes and complications of combined BAV and PCI with BAV alone. Methods: The study cohort consisted of 409 patients with severe aortic stenosis undergoing BAV from 1/2007 to 12/2010. Overall, 329 patients underwent BAV alone and 80 underwent concomitant PCI. Clinical and hemodynamic data, as well as acute and intermediate‐term outcomes, were collected. Results: At the operator's discretion PCI was done before BAV in 66 (82.5%) and after in 14 (17.5%). Patients who underwent concomitant procedures had a higher incidence of prior stroke and a lower incidence of atrial fibrillation. Procedure time and fluoroscopic time were significantly greater in the BAV/PCI group, (90.0 ± 36.6 vs. 72.8 ± 39.8, P = 0.002 and 20.5 ± 10.9 vs. 12.9 ± 7.0, P < 0.001). Significantly more radiographic contrast was used in the BAV/PCI group (95.1 ± 45.5 vs. 36.7 ± 38.4 cm³, P < 0.001. Serious adverse events occurred with equal frequency 13.7 and 17.3%, P = 0.44). Transfusion requirement was also similar (21.2% vs. 20.0%, P = 0.81). The frequency of a periprocedural increase in troponin or creatinine was also similar. In the BAV alone group the mortality rate was 48.6% (n = 160) during a mean follow‐up of 191 days, and in the BAV/PCI group the mortality rate was 40% (n = 32) during mean follow‐up of 175.5 day, P = 0.34. Conclusion: Combined BAV and PCI are safe and are associated with similar complications as BAV alone and may offer protection against myocardial ischemia during BAV. © 2011 Wiley Periodicals, Inc.     

二尖瓣狭窄并中度反流的经皮二尖瓣球囊扩张术42例及随访观察

目的　探讨二尖瓣狭窄 (MS)并中度反流 (MR)患者经皮二尖瓣球囊扩张术 (PBMV)近远期疗效。方法　采用Inoue单球囊对 42例风心病二尖瓣狭窄并中度反流患者行PAMV治疗。结果　二尖瓣口面积由 (0 92± 0 2 2 )cm2 增至 (1 94± 0 2 5 )cm2 (P <0 0 1) ;二尖瓣跨瓣压差由 (2 7± 1 0 1)kPa降至 (1 0 2± 0 5 6 )kPa(P <0 0 1) ;心功能由 (2 6 1± 0 2 2 )级改善至 (1 42± 0 46 )级 (P <0 0 1) ;左室最大前后径无明显变化 (P >0 0 5 )。 2例患者二尖瓣反流较术前加重。随访 37例患者 (18± 4)个月 ,二尖瓣口面积、左室最大前后径及心功能与术后比较 ,均无明显变化 (P >0 0 5 )。结论　掌握好病例选择 ,严格把握球囊扩张尺度 ,风心病二尖瓣狭窄并中度反流患者PBMV近、远期疗效满意     

Impella support following emergency percutaneous balloon aortic valvuloplasty in patients with severe aortic valve stenosis and cardiogenic shock

BackgroundTo investigate the feasibility and outcomes of Impella 2.5 support in patients with severe aortic valve stenosis (AS) and cardiogenic shock (CS), who underwent emergency percutaneous balloon aortic valvuloplasty (BAV) with or without percutaneous coronary intervention (PCI).Methods and resultsWe retrospectively analyzed a consecutive series of patients with severe AS and CS who underwent Impella 2.5 support following emergency BAV with or without subsequent PCI. Outcome data included 30-day outcomes, periprocedural as well as throughout the circulatory support period complications. Eight patients with severe AS and CS were identified. Impella 2.5 implantation was successful following emergency BAV in all patients attempted. Additional PCI was performed in four patients. No periprocedural deaths or periprocedural neurologic events occurred. Mean procedure time was 125.9 min (range 64–210 min). Mortality at 30 days was 50%.ConclusionsImpella 2.5 can be used as hemodynamic support in patients with severe AS and CS following emergency percutaneous BAV and may help to improve tolerability of PCI in these high-risk patients.